Strategic partnerships Trevi Therapeutics is a clinical-stage biopharma with a high-profile focus on chronic cough linked to IPF and ILD, presenting collaboration opportunities with larger pharma companies or specialty CROs in respiratory and rare disease spaces to accelerate trial programs and potential commercialization.

Clinical leadership With Haduvio being the first to show statistically significant cough reduction in IPF and RCC trials, there is a strong sales narrative for key opinion leaders and payer discussions, enabling early access programs and differentiated value propositions.

Regulatory momentum Active conference presence (ATS, ERS) and investor events indicate ongoing regulatory and scientific engagement, suggesting opportunities to position as a preferred partner for co-development or accelerated pathways in respiratory rare diseases.

Financial runway Significant funding raised (over 500 million in total; a recent 173 million offering) provides a solid foundation for expanding clinical programs, enabling BD teams to propose broader collaboration, licensing, or milestone-based deals to potential acquirers or licensees.

Global reach potential Although headquartered in New Haven with a focused pipeline, participation in European and international congresses signals interest in global adoption; sales opportunities exist in international markets through partnerships,](distribution agreements, or regional commercialization deals.